Hemostasis and fibrinolysis in delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage: A systematic review

Journal of Cerebral Blood Flow and Metabolism

Volumn 35, Issue 5, 2015, Pages 724-733

  Boluijt, Jacoline ^a   Meijers, Joost C M ^b,c   Rinkel, Gabriel J E ^a   Vergouwen, Mervyn D I ^a,c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b SANQUIN RESEARCH   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

biomarker; coagulation; delayed cerebral ischemia; fibrinolysis; hemostasis; microthrombosis; subarachnoid hemorrhage

Indexed keywords

D DIMER; THROMBOCYTE ACTIVATING FACTOR; VON WILLEBRAND FACTOR; BIOLOGICAL MARKER; FIBRINOLYTIC AGENT;

BRAIN ISCHEMIA; CEREBROSPINAL FLUID; DELAYED CEREBRAL ISCHEMIA; EMBASE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; MEDLINE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SUBARACHNOID HEMORRHAGE; SYSTEMATIC REVIEW; ANIMAL; COMPLICATION; INTRACRANIAL ANEURYSM; METABOLISM; PATHOPHYSIOLOGY;

ANIMALS; BIOMARKERS; BRAIN ISCHEMIA; FIBRINOLYSIS; FIBRINOLYTIC AGENTS; HUMANS; INTRACRANIAL ANEURYSM; SUBARACHNOID HEMORRHAGE;

EID: 84928824945     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1038/jcbfm.2015.13     Document Type: Review

References (49)

1. Roos YB, De Haan RJ, Beenen LF, Groen RJ, Albrecht KW, Vermeulen M. Complications and outcome in patients with aneurysmal subarachnoid haemorrhage: a prospective hospital based cohort study in the Netherlands. J Neurol Neurosurg Psychiatry 2000; 68: 337-341
2. de Rooij NK, Greving JP, Rinkel GJ, Frijns CJ. Early prediction of delayed cerebral ischemia after subarachnoid hemorrhage: development and validation of a practical risk chart. Stroke 2013; 44: 1288-1294
3. Cremers CH, van der Schaaf IC, Wensink EW, Greving JP, Rinkel GJ, Velthuis BK, et al. CT-perfusion and delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage: a systematic review and meta-Analysis. J Cereb Blood Flow Metab 2014; 34: 200-207
4. Dankbaar JW, de Rooij NK, Velthuis BK, Frijns CJ, Rinkel GJ, van der Schaaf IC. Diagnosing delayed cerebral ischemia with different CT modalities in patients with subarachnoid hemorrhage with clinical deterioration. Stroke 2009; 40: 3493-3498
5. Dankbaar JW, Rijsdijk M, van der Schaaf IC, Velthuis BK, Wermer MJ, Rinkel GJ. Relationship between vasospasm, cerebral perfusion, and delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. Neuroradiology 2009; 51: 813-819
6. Vergouwen MDI, Ilodigwe D, Macdonald RL. Cerebral infarction after subarachnoid hemorrhage contributes to poor outcome by vasospasm-dependent and-independent effects. Stroke 2011; 42: 924-929
7. Vergouwen MD, Vermeulen M, Coert BA, Stroes ES, Roos YB. Microthrombosis after aneurysmal subarachnoid hemorrhage: an additional explanation for delayed cerebral ischemia. J Cereb Blood Flow Metab 2008; 28: 1761-1770
8. Suzuki S, Kimura M, Souma M, Ohkima H, Shimizu T, Iwabuchi T. Cerebral microthrombosis in symptomatic cerebral vasospasm-A quantitative histological study in autopsy cases. Neurol Med Chir (Tokyo) 1990; 30: 309-316
9. Stein SC, Browne KD, Chen X-H, Smith DH, Graham DI. Thromboembolism and delayed cerebral ischemia after subarachnoid hemorrhage: an autopsy study. Neurosurgery 2006; 59: 781-787
10. Sabri M, Ai J, Lakovic K, D'abbondanza J, Ilodigwe D, Macdonald RL. Mechanisms of microthrombi formation after experimental subarachnoid hemorrhage. Neuroscience 2012; 224: 26-37
11. Friedrich B, Muller F, Feiler S, Scholler K, Plesnila N. Experimental subarachnoid hemorrhage causes early and long-lasting microarterial constriction and microthrombosis: an in-vivo microscopy study. J Cereb Blood Flow Metab 2012; 32: 447-455
12. Pisapia JM, Xu X, Kelly J, Yeung J, Carrion G, Tong H, et al. Microthrombosis after experimental subarachnoid hemorrhage: time course and effect of red blood cell-bound thrombin-Activated pro-urokinase and clazosentan. Exp Neurol 2012; 233: 357-363
13. Vergouwen MD, Vermeulen M, van Gijn J, Rinkel GJ, Wijdicks EF, Muizelaar JP, et al. Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies: proposal of a multidisciplinary research group. Stroke 2010; 41: 2391-2395
14. de Rooij NK, Rinkel GJ, Dankbaar JW, Frijns CJ. Delayed cerebral ischemia after subarachnoid hemorrhage: a systematic review of clinical, laboratory, and radiological predictors. Stroke 2013; 44: 43-54
15. Juvela S, Kaste M, Hillbom M. Platelet thromboxane release after subarachnoid hemorrhage and surgery. Stroke 1990; 21: 566-571
16. Juvela S, Hillbom M, Kaste M. Platelet thromboxane release and delayed cerebral ischemia in patients with subarachnoid hemorrhage. J Neurosurg 1991; 74: 386-392
17. O'Neill P, Walton S, Foy PM, Shaw MD. Does thrombin prevent cerebral vasospasm following aneurysmal subarachnoid haemorrhage? Br J Neurosurg 1992; 6: 313-319
18. Ameriso SF, Wong VLY, Ishii H, Quismorio FP, Jr, Giannotta SL, Meiselman HJ, et al. Hematogenous factors and prediction of delayed ischemic deficit after subarachnoid hemorrhage. Stroke 1992; 23: 1404-1409
19. Hirashima Y, Endo S, Kurimoto M, Tsukamoto E, Takaku A. Platelet-Activating factor and antiphospholipid antibodies in subarachnoid haemorrhage. Acta Neurochir (Wien) 1994; 128: 144-149
20. Hirashima Y, Endo S, Ohmori T, Kato R, Takaku A. Platelet-Activating factor (PAF) concentration and PAF acetylhydrolase activity in cerebrospinal fluid of patients with subarachnoid hemorrhage. J Neurosurg 1994; 80: 31-36
21. Itoyama Y, Fujioka S, Takaki S, Morioka M, Hide T, Ushio Y, et al. Significance of elevated thrombin-Antithrombin III complex and plasmin-(alpha)2-plasmin inhibitor complex in the acute stage of nontraumatic subarachnoid hemorrhage. Neurosurgery 1994; 35: 1055-1060
22. Hirashima Y, Nakamura S, Endo S, Kuwayama N, Naruse Y, Takaku A. Elevation of platelet activating factor, inflammatory cytokines, and coagulation factors in the internal jugular vein of patients with subarachnoid hemorrhage. Neurochem Res 1997; 22: 1249-1255
23. Hirashima Y, Nakamura S, Suzuki M, Kurimoto M, Endo S, Ogawa A, et al. Cerebrospinal fluid tissue factor and thrombin-Antithrombin III complex as indicators of tissue injury after subarachnoid hemorrhage. Stroke 1997; 28: 1666-1670
24. Niikawa S, Hara S, Ohe N, Miwa Y, Ohkuma A. Correlation between blood parameters and symptomatic vasospasm in subarachnoid hemorrhage patients. Neurol Med Chir (Tokyo) 1997; 37: 881-884
25. Fujii Y, Takeuchi S, Sasaki O, Minakawa T, Koike T, Tanaka R. Serial changes of hemostasis in aneurysmal subarachnoid hemorrhage with special reference to delayed ischemic neurological deficits. J Neurosurg 1997; 86: 594-602
26. Ikeda K, Asakura H, Futami K, Yamashita J. Coagulative and fibrinolytic activation in cerebrospinal fluid and plasma after subarachnoid hemorrhage. Neurosurgery 1997; 41: 344-349
27. Peltonen S, Juvela S, Kaste M, Lassila R. Hemostasis and fibrinolysis activation after subarachnoid hemorrhage. J Neurosurg 1997; 87: 207-214
28. Kasuya H, Shimizu T, Takakura K. Thrombin activity in CSF after SAH is correlated with the degree of SAH, the persistence of subarachnoid clot and the development of vasospasm. Acta Neurochir (Wien) 1998; 140: 579-584
29. Frijns CJ, Fijnheer R, Algra A, van Mourik JA, van Gijn J, Rinkel GJ. Early circulating levels of endothelial cell activation markers in aneurysmal subarachnoid haemorrhage: associations with cerebral ischaemic events and outcome. J Neurol Neurosurg Psychiatry 2006; 77: 77-83
30. Juvela S, Siironen J. D-dimer as an independent predictor for poor outcome after aneurysmal subarachnoid hemorrhage. Stroke 2006; 37: 1451-1456
31. Schebesch K-M, Woertgen C, Brawanski A, Rothoerl RD. A study of possible correlation between subarachnoid haemorrhage related vasospasm and the postbleed blood platelet count chart in a Caucasian population. Acta Neurochir 2007; 149: 387-391
32. Tseng M-Y, Hutchinson PJ, Turner CL, Czosnyka M, Richards H, Pickard JD, et al. Biological effects of acute pravastatin treatment in patients after aneurysmal subarachnoid hemorrhage: a double-blind, placebo-controlled trial. J Neurosurg 2007; 107: 1092-1100
33. Vergouwen MD, Bakhtiari K, van Geloven N, Vermeulen M, Roos YB, Meijers JC. Reduced ADAMTS13 activity in delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. J Cereb Blood Flow Metab 2009; 29: 1734-1741
34. Kasius KM, Frijns CJ, Algra A, Rinkel GJ. Association of platelet and leukocyte counts with delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage. Cerebrovasc Dis 2010; 29: 576-583
35. van Lier FA, Urbanus RT, de Rooij NK, Rinkel GJ, Frijns CJ. Lupus anticoagulant in patients with subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry 2012; 83: 89-90
36. Hirashima Y, Endo S, Nakamura S, Kurimoto M, Takaku A. Cerebrospinal fluid membrane-bound tissue factor and myelin basic protein in the course of vasospasm after subarachnoid hemorrhage. Neurol Res 2001; 23: 715-720
37. Hirashima Y, Hamada H, Kurimoto M, Origasa H, Endo S. Decrease in platelet count as an independent risk factor for symptomatic vasospasm following aneurysmal subarachnoid hemorrhage. J Neurosurg 2005; 102: 882-887
38. Hirashima Y, Kurimoto M, Tsukamoto E, Endo S, Takaku A. Anti-phospholipid antibodies and cerebral vasospasm following subarachnoid haemorrhage. Acta Neurochir (Wien) 1995; 135: 191-197
39. Dorhout Mees SM, van den Bergh WM, Algra A, Rinkel GJ. Antiplatelet therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2007; (4): CD006184
40. Vergouwen MD, Knaup VL, Roelofs JJ, de Boer OJ, Meijers JC. Effect of recombinant ADAMTS-13 on microthrombosis and brain injury after experimental subarachnoid hemorrhage. J Thromb Haemost 2014; 12: 943-947
41. Muroi C, Fujioka M, Mishima K, Irie K, Fujimura Y, Nakano T, et al. Effect of ADAMTS-13 on cerebrovascular microthrombosis and neuronal injury after experimental subarachnoid hemorrhage. J Thromb Haemost 2014; 12: 505-514
42. Dong JF, Moake JL, Nolasco L, Bernardo A, Arceneaux W, Shrimpton CN, et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 2002; 100: 4033-4039
43. Chauhan AK, Motto DG, Lamb CB, Bergmeier W, Dockal M, Plaimauer B, et al. Systemic antithrombotic effects of ADAMTS13. J Exp Med 2006; 203: 767-776
44. Chauhan AK, Kisucka J, Brill A, Walsh MT, Scheiflinger F, Wagner DD. ADAMTS13: a new link between thrombosis and inflammation. J Exp Med 2008; 205: 2065-2074
45. Motto DG, Chauhan AK, Zhu G, Homeister J, Lamb CB, Desch KC, et al. Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. J Clin Invest 2005; 115: 2752-2761
46. Zhao BQ, Chauhan AK, Canault M, Patten IS, Yang JJ, Dockal M, et al. von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke. Blood 2009; 114: 3329-3334
47. Wang L, Fan W, Cai P, Fan M, Zhu X, Dai Y, et al. Recombinant ADAMTS13 reduces tissue plasminogen activator-induced hemorrhage after stroke in mice. Ann Neurol 2013; 73: 189-198
48. Hirashima Y, Endo S, Nukui H, Kobayashi N, Takaku A. Effect of a plateletactivating factor receptor antagonist, E5880, on cerebral vasospasm after aneurysmal subarachnoid hemorrhage-open clinical trial to investigate efficacy and safety. Neurol Med Chir (Tokyo) 2001; 41: 165-175
49. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez ALOPTIMIST Trial Study Groupet al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003; 290: 238-247